Even-Sapir Einat
Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Semin Musculoskelet Radiol. 2007 Dec;11(4):312-21. doi: 10.1055/s-2008-1060334.
The most commonly used positron emission tomography (PET) tracer in clinical practice, fluorine-18 fluorodeoxyglucose ( (18)F-FDG) is a glucose analogue that directly gains entry in excess into tumor cells. It is therefore sensitive for the detection of early bone marrow involvement prior to any identifiable bone changes. The introduction of (18)F-FDG-PET in the imaging algorithms of various malignant diseases often obviates the need to perform a separate assessment of malignant bone involvement with conventional bone scintigraphy. After therapy, disappearance of (18)F-FDG accumulation indicates success even when the bone remains morphologically abnormal. Novel hybrid systems composed of PET and computed tomography (CT) allow for acquisition of both modalities in the same clinical setting and the generation of fused functional-anatomical images. This technique has been found to improve the diagnostic accuracy of PET in detecting malignant bone involvement. This article discusses the role of PET/CT, primarily (18)F-FDG PET/CT, in the assessment of malignant bone involvement in patients with primary bone sarcomas, common solid malignancies, lymphoma, and multiple myeloma.
临床实践中最常用的正电子发射断层扫描（PET）示踪剂氟-18氟脱氧葡萄糖（¹⁸F-FDG）是一种葡萄糖类似物，可直接过量进入肿瘤细胞。因此，它对于在任何可识别的骨骼变化之前检测早期骨髓受累很敏感。在各种恶性疾病的成像算法中引入¹⁸F-FDG-PET通常无需用传统骨闪烁显像对恶性骨受累进行单独评估。治疗后，即使骨骼在形态上仍异常，¹⁸F-FDG摄取的消失也表明治疗成功。由PET和计算机断层扫描（CT）组成的新型混合系统允许在同一临床环境中获取两种模态并生成融合的功能-解剖图像。已发现该技术可提高PET检测恶性骨受累的诊断准确性。本文讨论了PET/CT，主要是¹⁸F-FDG PET/CT在评估原发性骨肉瘤、常见实体恶性肿瘤、淋巴瘤和多发性骨髓瘤患者恶性骨受累中的作用。
